Literature DB >> 12393068

Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet function.

Serenella Rotondo1, Giuseppe Dell'Elba, Katarzyna Krauze-Brzósko, Stefano Manarini, Nicola Martelli, Romina Pecce, Virgilio Evangelista, Chiara Cerletti.   

Abstract

Polymorphonuclear leukocytes are strongly implicated in the pathogenesis of inflammatory disease. Polymorphonuclear leukocyte recruitment at sites of inflammation, mainly sustained by the beta2-integrins, is followed by the synthesis and release of inflammatory mediators, such as leukotrienes, proteolytic enzymes and reactive oxygen species. Functional and metabolic interactions between polymorphonuclear leukocytes and platelets can contribute to and exacerbate the process. The effects of the dual 5-lipoxygenase and cyclooxygenase inhibitor licofelone ([2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid) were studied on arachidonic acid transcellular metabolism occurring between polymorphonuclear leukocytes and platelets. The formation of leukotriene C(4), a leukotriene A(4)-derived metabolite, by mixed polymorphonuclear leukocyte/platelet suspensions stimulated with 10 microM A23187 was inhibited by licofelone with an IC(50) of 3.8 +/- 0.07 microM. The formation of 5,12-di-hydroxy-eicosatetraenoic acid (HETE) was abolished at concentrations > or = 10 microM. Licofelone also inhibited the generation of reactive oxygen species by polymorphonuclear leukocytes stimulated with 1 microM n-formyl-methionyl-leucyl-phenylalanine (fMLP), 10 nM complement fraction 5a (C5a) and 1 microM platelet activating factor (PAF) with IC(50)s of 24.4 +/- 0.6, 11.0 +/- 1.5 and 11.7 +/-1.2 microM; elastase release induced by the three agonists was inhibited with IC(50)s of 12.2 +/- 2.2, 23.5 +/- 8 and 2.6 +/- 1 microM, respectively. Homotypic polymorphonuclear leukocyte aggregation induced by fMLP, C5A and PAF was inhibited by licofelone with IC(50)s of 23.7 +/- 4.8, 15.6 +/- 3.4 and 15.4 +/- 4 microM, respectively. The present study extends the anti-lipoxygenase and anti-cyclooxygenase activities of licofelone to the production of arachidonic acid metabolites generated as a consequence of polymorphonuclear leukocyte-platelet transcellular metabolism and to polymorphonuclear leukocyte responses relevant to the pathogenesis of inflammation. The coexistence within the same molecule of a wide spectrum of anti-inflammatory properties is of interest. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393068     DOI: 10.1016/s0014-2999(02)02385-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

Review 1.  Rationally designed multitarget agents against inflammation and pain.

Authors:  S H Hwang; A T Wecksler; K Wagner; B D Hammock
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 2.  Combined lipoxygenase/cyclo-oxygenase inhibition in the elderly: the example of licofelone.

Authors:  Arrigo F G Cicero; Giuseppe Derosa; Antonio Gaddi
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

3.  The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products.

Authors:  L Fischer; M Hornig; C Pergola; N Meindl; L Franke; Y Tanrikulu; G Dodt; G Schneider; D Steinhilber; O Werz
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

4.  Cyclooxygenase-2 and 5-lipoxygenase in dogs with chronic enteropathies.

Authors:  S D Dumusc; E C Ontsouka; M Schnyder; S Hartnack; C Albrecht; R M Bruckmaier; I A Burgener
Journal:  J Vet Intern Med       Date:  2014-09-30       Impact factor: 3.333

Review 5.  Potential Antifungal Targets against a Candida Biofilm Based on an Enzyme in the Arachidonic Acid Cascade-A Review.

Authors:  Xinning Liu; Decai Wang; Cuixiang Yu; Tao Li; Jianqiao Liu; Shujuan Sun
Journal:  Front Microbiol       Date:  2016-12-06       Impact factor: 5.640

6.  Synergistic Antifungal Effect of Fluconazole Combined with Licofelone against Resistant Candida albicans.

Authors:  Xinning Liu; Tao Li; Decai Wang; Yilei Yang; Wenwen Sun; Jianqiao Liu; Shujuan Sun
Journal:  Front Microbiol       Date:  2017-11-07       Impact factor: 5.640

Review 7.  Activity and potential role of licofelone in the management of osteoarthritis.

Authors:  Arrigo F G Cicero; Luca Laghi
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.